Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | CCNC | P24863 | 2/20 | 0.53 |
| ▸ | CDK8 | P49336 | 2/20 | 0.53 |
| ▸ | CHUK | O15111 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30860478 | 1.00 | FYN (0.57) | FYNCDC7CCNCCDK8CHUK | |
| Hydrochloric Acid SCHEMBL30037727 | 0.98 | FYN (0.56) | FYNCDC7CCNCCDK8CHUK | |
| SCHEMBL6999225 | 0.88 | DHODH (0.63) | CCNCCDK8DHODHERN1CCNT1 | |
| SCHEMBL31422694 | 0.86 | PARP1 (0.64) | CCNCCDK8DHODHERN1CCNT1 | |
| SCHEMBL2431097 | 0.86 | PARP1 (0.64) | CCNCCDK8DHODHERN1CCNT1 | |
| SCHEMBL27623946 | 0.85 | MEN1 (0.55) | AURKAPRKCIKMO | |
| SCHEMBL43553 | 0.84 | DHODH (0.70) | FYNCDC7DHODHERN1MKNK1 | |
| SCHEMBL29788172 | 0.84 | DHODH (0.70) | FYNCDC7DHODHERN1MKNK1 | |
| SCHEMBL29627221 | 0.83 | KMO (0.71) | DHODHAURKAPRKCIIKBKEKMO | |
| SCHEMBL207161 | 0.83 | KMO (0.71) | DHODHAURKAPRKCIIKBKEKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4713152-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2307387-B1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8071586-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| CN-101965189-A | Activators of pro-caspase 3, 6 and 7 | UNIV CALIFORNIA | 2011-02-02 | — | — | CN | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2010006938-A1 | NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-21 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009089508-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | FYN 1345/4885CDC7 3722/4885CCNC 899/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | FYN 1029/4885CDC7 4096/4885CCNC 3177/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | FYN 1029/4885CDC7 4096/4885CCNC 3177/4885 |
| US-20100016282-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | FYN 691/4885CDC7 2216/4885CCNC 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.